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doi:10.1016/j.jtcvs.2006.04.055bjective: The introduction of drug-eluting stents significantly reduced restenosis
nd reinterventions in patients undergoing percutaneous coronary interventions.
his study compares results of Cypher stenting with those of surgical arterial
evascularization in patients with diabetes mellitus.
ethods: From May 2002 through May 2005, 523 consecutive diabetic patients
nderwent myocardial revascularization: 244 underwent percutaneous coronary
nterventions incorporating drug-eluting stents, and 279 were treated surgically. All
ingle-vessel patients in the surgical group were treated with the left internal
horacic artery, and most multivessel patients were treated with 2 internal thoracic
rteries. After propensity score matching, 2 groups (93 patients each) were used to
ompare the 2 revascularization modalities.
esults: The number of coronary vessels treated per patient was higher in the
urgical group (2.72 vs 1.75, P .001). Follow-up ranged between 6 and 42 months
mean, 19 months). Overall mortality (early and late) was 3.2% in the surgical group
nd 2.2% in the Cypher group (P  .65). Two-year angina-free survival and
eintervention-free survival (Kaplan-Meier) of the surgical group were 88% and
5%, respectively, compared with 47.8% (P  .001) and 83.6% (P  .01),
espectively, in the percutaneous coronary intervention group. Cox proportional
azards modeling revealed assignment to the Cypher group to be the only predictor
f reintervention (odds ratio, 3.86; 95% confidence interval, 1.25-11.9). Assignment
o the Cypher group (hazard ratio, 5.92; 95% confidence interval, 2.96-11.87) and
nsulin treatment (hazard ratio, 2.06; 95% confidence interval, 1.06-4.02) were
ndependent predictors of angina recurrence.
onclusions: The midterm clinical outcome of diabetic patients who underwent
urgical arterial revascularization is better than that of patients undergoing percu-
aneous coronary intervention treated with drug-eluting stents.
schemic heart disease is a leading cause of death in diabetic patients.1 Therefore
an increasing number of diabetic patients are referred today for surgical or
percutaneous revascularization,2 leading to a significant increase in the pre
ence of diabetic patients undergoing coronary artery bypass grafting (CABG) or
ercutaneous coronary intervention (PCI).3
Surgical revascularization of the left anterior descending artery (LAD) with the
nternal thoracic artery (ITA) in patients with multivessel disease is still the only
roved method of improving event-free survival.4,5 In the subset of patients w
iabetes mellitus in the Bypass Angioplasty Revascularization Investigation
tudy,6,7 which compared PCI with CABG, LAD revascularization with the 
as found to be an independent predictor of survival. Similar findings were reported
ater in the subgroup of patients with diabetes in the Arterial Revascularization




Dignificantly better than that of diabetic patients treated with bare-metal stents.
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AConsiderable reduction of restenosis and reintervention
ates was recently reported with the introduction of drug-
luting stents (DESs).9 Improved angiographic and clinica
utcome was also reported among diabetic patients.10,11 We
herefore decided to compare the midterm clinical outcome
f CABG in diabetic patients with that of PCI incorporating
ESs.
atients and Methods
ive hundred twenty-three consecutive diabetic patients underwent
ither CABG (n  279) or Cypher (Cordis Corp, Warren, NJ)
mplantation (n  244) between May 2002 and May 2005. The
ypher stent was the only DES available in our centers during the
tudy period.
djustment for Patient Selection
he probability (propensity score) that a patient would receive a
ypher stent or undergo CABG, according to the preprocedural
ariables (all variables included in Table 1), was determine
sing a saturated logistic regression model to take into account the
ifferent patient profiles.12 Patients from the Cypher group we
hen matched with patients from the CABG group according to
heir propensity score in such a way that the difference between the
ropensities in each pair of matched patients was less than 10%.
his revealed 93 pairs of propensity-matched patients, on whom
omplete follow-up was performed. Demographic and clinical
reprocedural data of the propensity-matched patients are shown
n Tables 2 and 3. It can be seen that after matching, patie
ore evenly distributed between the 2 groups.
During the study period, selection criteria for surgical interven-
ion versus PCI were mainly technical. In principle, there was a
reference to refer patients for surgical intervention for the fol-
owing reasons:
1. complex type C lesions (calcified coronary arteries, lesion
length20 mm, twisted arteries, or suspicion of a thrombus
in an artery) or bifurcation lesion involving a major diag-
onal or marginal branch;
2. complete occlusion;
3. nonavailability of Cypher stent; or
4. patient’s preference.
In the PCI group stent implantation was performed after bal-
oon angioplasty dilatation. All patients received aspirin (325 mg
aily) before and after the procedure and clopidogrel (Plavix,
anofi; a loading dose of 300 mg the day before the procedure and
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CI  confidence interval
HR  hazard ratio
ITA  internal thoracic artery
LAD  left anterior descending artery
MACEmajor adverse cardiovascular event
MI myocardial infarction
PCI  percutaneous coronary intervention
TVR  target vessel revascularization
RE
TR5 mg daily thereafter). During the procedure, all patients were f
62 The Journal of Thoracic and Cardiovascular Surgery ● Octore
reated intravenously with heparin. Intravenous platelet glycopro-
ein IIb/IIIa inhibitors (eptifibatide [Integrilin, Schering-Plough,
enilworth, NJ] or tirofiban [Aggrastat, Merck, Sharp and Dohme,
hitehouse Station, NJ]) were used only in 10 members of the PCI
roup. All left anterior descending lesions in the PCI group were
reated with DESs. In most patients only one Cypher stent was
sed for the vessel treated. However, more than one Cypher stent
as used if required (eg, long lesion, dissection, or bifurcation).
ESs, bare-metal stents, or plain balloon angioplasty were used
or non-LAD lesions. Forty-two patients with multivessel disease
ere treated with 2 or more Cypher stents. Bare stents were used
n 18 patients with tortuous or calcified coronary vessels. Percu-
aneous transluminal coronary angioplasty was used in 8 patients
ith vessels smaller than 2.25 mm or in patients with focal in-stent
estenosis.
Fifty-four (58%) of the patients treated surgically were oper-
ted on without extracorporeal circulation. All ITAs were dis-
ected as skeletonized vessels and used preferentially for left-sided
LAD and circumflex artery) arterial revascularization. In all pa-
ients in the surgical group, ITAs were used for LAD revascular-
zation. In patients with single-vessel disease, we used an in situ
eft ITA.
The right ITA, either as an in situ graft or as a free graft
ttached end-to-side to the left ITA (composite T-graft), was used
n 74 (79%) patients with multivessel disease. In 17 patients
eft-sided revascularization was achieved with radial arteries for
omposite T-grafting.
Right coronary system (posterior descending artery or postero-
ateral branch of the right coronary artery) revascularization was
erformed with a saphenous vein graft in 19 patients, the radial
rtery in 9 patients, the right ITA in 3 patients (distal end of the








ge 70 y 92 (33%) 65 (26.6%) .288
emale sex 49 (17.6%) 54 (22.1%) .232
hronic renal failure 7 (2.5%) 4 (1.6%) .489
cute myocardial infarction (7 d) 44 (15.8%) 35 (14.3%) .650
jection fraction 30% 18 (6.5%) 14 (5.7%) .734
rior PCI 55 (19.7%) 74 (30.3%) .005
n-stent restenosis 7 (2.5%) 11 (4.5%) .211
mergency 29 (10.4%) 4 (1.6%) .000
ntra-aortic balloon pump 11 (2.1%) 2 (0.8%) .022
besity 24 (27.6%) 28 (32.2%) .508
eft main 83 (29.7%) 23 (9.4%) .022
ne-vessel disease 6 (2.2%) 90 (37%)
wo-vessel disease 57 (20.4%) 101 (41.4%) .000
hree-vessel disease 216 (77.4%) 52 (21.3%)
ight coronary artery
revascularization
166 (59.9%) 36 (14.8%) .000
otal occlusion 86 (30.8%) 27 (11.1%) .000
ABG, Coronary artery bypass grafting; PCI, percutaneous coronary inter-
ention, angioplasty or stent.CT



























































































Ben-Gal et al Evolving Technology
ET
Aefinitions and Data Collection
atients’ data were analyzed according to the Society of Thoracic
urgeons’ National Cardiac Surgery Database guidelines and def-
nitions. Diabetic patients included patients treated with insulin or
ral hypoglycemic agents. Cardiac mortality was defined as death
ccurring in relation to myocardial infarction (MI), cardiac ar-
hythmia, out-of-hospital sudden death, or deteriorating congestive
eart failure. Undetermined causes of death were regarded as
ardiac. Major adverse cardiovascular events (MACEs) were de-
ned as the occurrence of a nonfatal MI, the need for repeat
evascularization, or cardiac mortality. Target vessel revascular-
zation (TVR) was defined as reintervention in a vessel treated
reviously with a DES or arterial graft (ITA or radial). Follow-up
as obtained by means of telephone questionnaire and from the
ational Registry database.
tatistical Analysis
escriptive statistics were performed first, followed by univariate
nalysis. Continuous variables were compared by using t tests, and
ategoric variables were compared by using 2 or Fisher exact
ests, as appropriate. Kaplan-Meier curves were used to show
reedom from time-related events, and the Cox proportional haz-
rds model was used to identify predictors associated with time-
elated events. A separate analysis was performed for each time-
elated event. The time-related events studied were reangina, any









ge 70 y 31 (33.3%) 38 (40.9%) .288
emale sex 19 (20.4%) 24 (25.8%) .385
nsulin-dependent diabetes
mellitus
9 (9.7%) 14 (15.1%) .265
ypertension 64 (67.7%) 56 (47.1%) .285
yperlipidemia 56 (60.2%) 56 (60.2%) 1.000
hronic obstructive pulmonary
disease
5 (5.4%) 3 (3.2%) .470
hronic renal failure (Cr 1.8) 4 (4.3%) 3 (3.2%) .700
eripheral vascular disease 8 (8.6%) 5 (4.5%) .388
ld myocardial infarction 32 (34.4%) 24 (25.8%) .201
cute myocardial infarction (7 d) 15 (16.1%) 11 (11.8%) .398
jection fraction 30% 3 (3.2%) 1 (1.1%) .312
rior PCI 38 (40.9%) 26 (28%) .064
rior PCI to left anterior
descending artery
22 (23.7%) 10 (10.8%) .211
n-stent restenosis 13 (14%) 7 (7.5%) .156
mergency 3 (3.2%) 3 (3.2%) 1.000
epeat operation 1 (1.1%) 6 (6.5%) .054
ongestive heart failure 11 (11.8%) 7 (7.5%) .321
ntra-aortic balloon pump 1 (1.1%) 0 (0%) .316
besity 24 (40.7%) 35 (37.6%) .083
ABG, Coronary artery bypass grafting; Cr, creatinine; PCI, percutaneous
oronary intervention, angioplasty or stent.
RE
TReintervention, target vessel reintervention, and MACEs. t
The Journal of Thoraciceliability of the Analysis
he bootstrap resampling technique was used to ascertain the
eliability of the findings.13 Patients were drawn at random fro
he 93 patient pairs with replacement. This was repeated to con-
truct a new data set of 186 observations, which could contain one
r more duplicates of patients. This random sampling process was
epeated 1000 times to create 1000 differently constituted data
ets. We then performed the Cox proportional hazards model on
ach new dataset and inquired how often each variable in the
odel would be selected as a risk factor at a P value of less than
05. Variables that appeared more than 50% of the time as inde-
endent predictors were considered significant predictors.
esults
emographic and clinical preprocedural and periprocedural
ata of the 2 groups before matching are displayed in 
. After matching, the 2 groups were similar in most
perative characteristics (Table 2). However, bifurcati
esions and total occlusion were more prevalent in the
ABG group (Table 3).
The average number of coronary vessels treated in the
ABG and PCI groups was 2.72 0.81 versus 1.75 0.73,
espectively (P .001). Despite the fact that the groups had
similar preoperative extent of coronary artery involve-
ent, more patients in the CABG group had revasculariza-
ion of 3 vessels (59.8%), and more in the Cypher group
38.7% vs 1.1%, P  .000) had revascularization of only 1
essel (Table 3), accounting for incomplete revasculari
ion14 in 46.2% of the Cypher group compared with 31
f the CABG group (P  .001). Thirty-day mortality was
.1% in the CABG group and 0% in the Cypher group (P
316). Early postprocedural unfavorable outcome events in








eft main 10 (10.8%) 4 (4.3%) .095
ne-vessel disease 3 (3.2%) 5 (5.4%)
wo-vessel disease 31 (33.3%) 44 (47.3%) .085
hree-vessel disease 59 (63.4%) 44 (47.3%)
essels treated
One-vessel 1 (1.1%) 36 (38.7%)
Two-vessel 37 (39.7%) 44 (47.3%) .000
Three or more vessels 55 (59.2%) 13 (14%)
Right coronary artery
revascularization
33 (35.5%) 31 (33%) .758
Circumflex revascularization 88 (94.6%) 37 (39.8%) .000
Bifurcation lesion 31 (33.3%) 13 (14%) .002
Total occlusion 22 (23.7%) 6 (6.5%) .001
ABG, Coronary artery bypass grafting. *Seventy-three (79%) of the 92
atients with multivessel disease were treated with 2 internal thoracic
rteries.
CT
EDhe Cypher group included deterioration of renal function






































































3 [3.4%] patients), leading to chronic dialysis in 1 (1.1%)
atient and 2 (2.3%) periprocedural MIs. In the CABG group
here were 2 (2.3%) perioperative MIs, 1 (1.1%) stroke, and 1
ternal infection, and 5 (5.7%) patients experienced a tempo-
ary deterioration of renal function. Follow-up was 100% com-
lete and ranged between 6 and 42 months (mean, 19 months).
eturn of Angina
ngina returned in 43 (46.2%) patients in the Cypher group
ompared with 12 (12.9%) patients in the CABG group.
wo-year angina-free survival (Kaplan-Meier) of the pa-
ients in the CABG group was 88% compared with 47.8% in
he patients in the PCI group (P  .001, log-rank test;
igure 1).
Assignment to the Cypher group and preprocedural treat-
ent with insulin were found to be associated with in-
reased risk of early angina return in multivariate analysis
Cox proportional hazards model: assignment to the Cypher
roup, hazard ratio [HR]  5.92, 95% confidence interval
CI] 2.96-11.87; insulin treatment, HR 2.06, 95% CI
.06-4.02).
In the surgical group multivariate (Cox proportional haz-
rds model) analysis did not identify any specific preoper-
tive (Table 2) or operative (Table 3) characteristics, inc
ng the use of the off-pump technique, to be associated with
ncreased risk of reangina. In the Cypher group angina
eturned in 6 (85.7%) of the 7 patients who underwent PCI
ecause of in-stent restenosis in the LAD. However, in-stent
estenosis did not emerge as an independent predictor of
eangina in the Cox proportional hazards model.
eintervention
hirty-seven patients in the Cypher group and 20 in the
ABG group underwent postoperative thallium single pho-
igure 1. Angina-free survival of the Cypher versus coronary
rtery bypass grafting (CABG) groups (Kaplan-Meier).
RE
TRon emission computed tomography, the results of which o
64 The Journal of Thoracic and Cardiovascular Surgery ● Octoere found to be positive in 14 (15%) of the Cypher group
ompared with 2 (2.2%) of the CABG group. Twenty-one
f the Cypher group and 9 of the CABG group were referred
or coronary angiography.
During the follow-up period, there were 4 (4.3%) rein-
erventions (2 surgical and 2 PCI) in the CABG group
4.3%) and 21 (22.6%; 2 surgical and 19 PCI) in the Cypher
roup. Twelve reinterventions in the Cypher group were to
Cypher-treated vessel, 3 were to a vessel treated previ-
usly with a bare-metal stent, 2 were to vessels treated with
lain balloon angioplasty, and 4 were in coronary vessels
hat were not treated in the first PCI.
Two-year reintervention-free survival (Kaplan-Meier) of
he patients in the CABG group was 95% compared with
3.6% in the Cypher group (P  .01, log-rank test; Figure 2
he Cox proportional hazards model revealed assignment to
he Cypher group to be the only independent predictor of
eintervention (HR, 3.86; 95% CI, 1.25-11.90).
Separate analysis of risk factors for reintervention in the
ypher group revealed in-stent restenosis in the LAD to be
ssociated with increased risk for reintervention (42.9% vs
1.6% in patients without this risk factor). In-stent resteno-
is was the only independent predictor for reintervention by
sing the Cox proportional hazards model (HR, 3.87; 95%
I, 1.07-19.28). None of the preoperative or operative ex-
lanatory variables, including the off-pump or on-pump
echniques, was associated with increased risk for reinter-
ention in the surgical group.
arget Vessel Reintervention
he purpose of this study was to compare PCI treatment
ith DESs with surgical treatment with arterial grafts. We
herefore defined TVR in the surgical group as a reinterven-
ion in a vessel treated previously with an arterial graft (ITA
igure 2. Reintervention-free survival (Kaplan-Meier). CABG, Cor-
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There were 12 (12.5%) TVRs in the Cypher group and 3
3.2%) in the CABG group during the follow-up period.
wo-year TVR-free survival (Kaplan-Meier) in the CABG
roup (95%) was significantly better than that in the Cypher
roup (87%; P  .038, log-rank test; Figure 3).
The Cox proportional hazards model revealed assign-
ent to the Cypher group to be the only independent pre-
ictor of TVR (HR, 5.9; 95% CI, 1.35-25.9).
The bootstrap resampling technique showed that assign-
ent to the Cypher group was an independent predictor of
VR in close to 600 of the 1000 analyses performed and
as the only significant predictor of TVR, emerging more
han 50% of the time.
ajor Adverse Cardiovascular Events
uring the follow-up period, the occurrence of MACEs
cardiac mortality, MI, or reintervention) was higher in the
ypher group (23.6% [22 events] vs 8.6% [8 events]). There
as one late MI in the CABG group, compared with 5 in the
ypher group. However, assignment to the Cypher group
as not found to be an independent predictor of MACEs.
oreover, the difference in actuarial occurrence of MACEs
etween groups did not reach statistical significance (P 
105, Figure 4).
The only independent predictor of MACEs using the Cox
roportional hazard model was peripheral vascular disease
HR, 3.24; 95% CI, 1.09-9.61).
Congestive heart failure (HR, 6.62; 95% CI, 1.55-20.57)
nd incomplete revascularization (HR, 4.17; 95% CI,
-17.54) were independent predictors for MACEs in the
urgical group, and in-stent restenosis was the only inde-
endent predictor for MACEs in the Cypher group (HR, 6.2;
igure 3. Target vessel revascularization (TVR), Cypher stents
ersus arterial grafts (Kaplan-Meier).
RE
TR5% CI, 1.48-26.32). 8
The Journal of Thoraciciscussion
n the prestent era, studies comparing results of CABG and
CI showed similar occurrence of death and MI but higher
ates of reinterventions and early return of angina in the
atients in the PCI group.15 Comparable long-term surviva
as demonstrated in most patients, with the exception of
iabetics.6,7,16
In the Arterial Revascularization Therapy Study similar
ndings were reported in a subgroup of 207 diabetic pa-
ients treated with stents.8 Survival of diabetic patien
reated surgically was better than survival of patients treated
ith bare-metal stents.
The improved clinical and angiographic outcome re-
orted recently with DESs also included the subset of
iabetic patients.10,11 However, the reported occurrenc
f MACEs and TVR was still higher in diabetic patients
hen compared with that seen in nondiabetic patients.
The current report is a retrospective cohort study describ-
ng our initial and midterm experience with Cypher stenting
n diabetic patients. Results are compared with those of
iabetic patients undergoing surgical arterial myocardial
evascularization.
Propensity score analysis was used to control for differ-
nces in preprocedural patient data. Propensity scores iden-
ified 186 patients, 93 for each group, with comparable
reprocedural and periprocedural characteristics. After a
ean follow-up of 19 months, which is long enough for the
evelopment of in-stent restenosis,17 survival was similar
owever, more than 40% of the Cypher-treated patients
xperienced early return of angina, and only 83% were free
f reintervention. Two-year (Kaplan-Meier) angina-free
urvival and reintervention-free survival of the surgical pa-
ients were significantly better (88% and 95% vs 47% and
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AMultivariate analysis with the Cox proportional hazards
odel defined assignment to the Cypher group to be the
nly significant predictor of reintervention and TVR and,
ogether with insulin treatment, was also an independent
redictor of reangina.
Another important finding is the relatively poor outcome
f Cypher stenting in diabetic patients with LAD in-stent
estenosis.
The number of patients enrolled is relatively small be-
ause of the matching protocol, and important covariates
mainly technical), such as vessel diameter and lesion
ength, were not included in the analysis. These technical
arameters, which are less important in the surgical group,
ight affect restenosis, reangina, and reintervention in the
CI group. Larger prospective multicenter studies are re-
uired to determine their importance in patients selected for
CI or surgical intervention in this evolving era of DESs.
nother limitation of this study is the relatively short follow-up
eriod (mean, 19 months). There is growing evidence that
ESs might develop delayed thrombosis related to delayed
ndothelialization, hypersensitivity to the stent polymer, or
iscontinuation of antiplatelet treatment.18,19 Longer follow-up
hat might also reveal statistical significance in MACEs is
herefore required.
In conclusion, the midterm clinical outcome of diabetic
atients treated surgically is still better than that of patients
reated with Cypher stents. However, the reangina and re-
ntervention gap20 between surgical intervention and PC
ight be reduced further by more extensive use of DESs in
he right coronary artery and circumflex territory and avoid-
ng PCI in diabetic patients with in-stent restenosis in the
AD.
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